Supplementary Table 1, Figures 1 - 3 from Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an &lt;i&gt;In Vivo&lt;/i&gt; Model of Childhood Astrocytoma